Glaucoma, which affects an estimated 57 million people worldwide, is an eye condition caused by too much pressure around the eye, which can damage the optical nerve and lead to irreversible blindness.

Santen Inc., the U.S. subsidiary of Santen Pharmaceutical Co., and Ube Corp. have received FDA approval for their Omlonti 0.002 percent eye drops, which are designed to reduce elevated intraocular ...

Endoscopic cyclophotocoagulation had better effect at early stages and ultrasound cycloplasty had higher safety and tolerance when treating intraocular pressure (IOP) in patients with secondary ...

Sight Sciences, Inc. has announced that new data on the OMNI® Surgical System will be presented at the 2025 American Glaucoma Society Annual Meeting, showcasing significant clinical outcomes in ...

The U.S. FDA approved Santen Pharmaceutical Co. Ltd.’s and UBE Industries Ltd.’s Omlonti (omidenepag isopropyl) ophthalmic solution for reducing elevated intraocular pressure in patients with primary ...

A minimally invasive surgical procedure for glaucoma designed to reduce intraocular pressure (IOP) has been found to have a high degree of success and significantly reduce the use of drugs for the ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

Shuchi Patel, MD: Good afternoon, Dr. Ruth Williams. Thank you so much for taking the time to have a discussion with us regarding a topic that is of emerging interest. Today we're going to talk about ...